细胞死亡,分子向疗法和EGFR突变肺癌中的代谢重编程
Himani Joshi1, M Saeed Sheikh1
1Department of Pharmacology, State University of New York, Upstate Medical University, 750 E Adams Street, Syracuse, NY 13210, USA.
表皮生长因子受体 (EGFR) 突变通过改变细胞信号和新陈代谢驱动非小细胞肺癌 (NSCLC). 了解这些变化有助于开发向疗法,克服对EGFR抑制剂的耐药性.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症新陈代谢 癌症新陈代谢
背景情况:
- 非小细胞肺癌 (NSCLC) 是全球癌症死亡的主要原因.
- 遗传异常,特别是表皮生长因子受体 (EGFR) 的突变,是NSCLC的关键驱动因素.
- 细胞代谢的改变越来越被认为是癌症发展和进展的关键因素.
研究的目的:
- 审查EGFR突变对NSCLC细胞增殖,生存和代谢重编程的影响.
- 讨论EGFR氨酸激酶抑制剂 (TKI) 的作用机制和临床使用.
- 探索EGFR-TKI耐药性的挑战和潜在的治疗策略,包括EGFR突变NSCLC的免疫治疗反应.
主要方法:
- 关于研究NSCLC中的EGFR突变的文献综述.
- 分析受EGFR突变影响的信号通路.
- 检查与EGFR变化相关的代谢重编程.
- 对EGFR-TKI疗效和耐药性机制的临床数据的审查.
主要成果:
- 在NSCLC中,EGFR突变显著影响细胞增殖,生存途径和代谢重编程.
- EGFR-TKIs通过抑制突变EGFR信号来诱导细胞死亡,但耐药性仍然是一个临床挑战.
- 第四代EGFR-TKI正在开发中,以克服耐药性.
- EGFR突变NSCLC往往对免疫疗法的反应有限,潜在的机制涉及瘤代谢和信号的改变.
结论:
- 用TKI向突变EGFR是NSCLC治疗的基石.
- 了解突变EGFR信号和代谢重编程之间的相互作用对于开发新的个性化治疗策略至关重要.
- 进一步研究克服TKI耐药性和改善EGFR突变NSCLC免疫疗法的疗效是有必要的.
更多相关视频
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
相关概念视频
Targeted Cancer Therapies
There are several types of targeted therapies against...
Mitogens and the Cell Cycle
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
